A Phase II Biomarker Trial of Everolimus in Patients With Advanced Renal Cell Carcinoma.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 04 Jul 2017
At a glance
- Drugs Everolimus (Primary)
- Indications Renal cancer
- Focus Biomarker; Pharmacodynamics
- 28 Jun 2017 Planned End Date changed from 1 Jun 2017 to 1 Jun 2018.
- 28 Jun 2017 Planned primary completion date changed from 1 Jan 2017 to 1 Jan 2018.
- 10 Jun 2017 Biomarkers information updated
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History